hATTR-PN

A committee of the U.S. Food and Drug Administration (FDA) has endorsed Onpattro (patisiran) for the treatment of the ATTR amyloidosis with cardiomyopathy (ATTR-CM),…

Medication adherence is crucial to managing familial amyloid polyneuropathy (FAP). Left untreated, FAP can have life-threatening consequences. As an article published…

An international panel of patient advocates and healthcare providers has published the first set of recommendations outlining steps for the holistic care of people living…

A rare mutation in the TTR gene was identified as the cause of familial amyloid polyneuropathy (FAP) in a family in China whose first…

After a hiatus of three years, it is with a mix of emotions that I return to writing this column. Allow me to reintroduce…

On Sunday, March 19, I appeared on New Zealand’s 1News to discuss my journey as a caregiver to my late husband, Aubrey, who had…

Amvuttra (vutrisiran) provided significant clinical benefits in multiple measures of quality of life and physical function in people with familial amyloid polyneuropathy (FAP),…

A 63-year-old man in Japan with a large bulge in his right arm bicep, called “Popeye sign,” was diagnosed with late-onset familial amyloid polyneuropathy…

AstraZeneca has added Latin America to the list of regions in which it has exclusive commercialization rights for eplontersen, an investigational therapy…

This column has been a year in the making. When my late husband, Aubrey, passed away in May 2022 from hereditary ATTR amyloidosis,…